Clinical Trial Search

Primary: The Percentage Change in HbA1c Level From Baseline to 12 Weeks — -11.1; 0.0 percentage change

Primary: Median Percent Change From Baseline to Week 6 in LDL-c in FDC and RSG Monotherapy — -39.9; 5.4 Percent change in LDL-c — p=<0.0001

Primary: Change From Baseline for Mean Hemoglobin A1c (HbA1C) — 6.9; -0.5 Percent of glycosylated hemoglobin

Primary: Percentage of Patients Attained Blood Glucose Control Target Defined as Glycated Haemoglobin A1c (HbA1c)<7%, According to 2015 American Diabetes Association (ADA) and…

Primary: Number of Index Dates — 91634; 33238; 28211; 26192 Number of Prescriptions

Primary: Change in Weight From Baseline at 12 Months or More — -8.37 Kg — p=<0.05

Primary: Ability of Different Screening Tests Which Can be Performed Opportunistically (During Outpatient Visits -- at Any Time of Day, Regardless of Meal Status) to Predict…

Primary: Percentage of Participants Who Had One or More Adverse Reactions — 5.41; 1.20; 0.98; 0.00 Percentage of Participants

Primary: Number of Participants Experiencing Hypoglycemic Episodes in the 6 Months Prior to Enrollment — 305 Participants

Primary: Beta-cell Function - C-peptide AUC (Area Under the Curve) — 2096; 1725 ng*min/mL

Primary: Number of Participants Achieving Hemoglobin A1C (HbA1C) <7% — 378 participants

Primary: Change From Baseline in Homeostatic Model Assessment Fasting Beta Cell Function (HOMA % B) at 4 Years — 50.2; 48.3 Percentage of Beta Cell Function — p=0.24

Primary: Percent of Participants With a Mean Blood Glucose Concentration of Less Than 70 mg/dL — 28; 31 percentage of participants

Primary: Difference in Insulin Resistance (HOMA) Between Treatments After 12 Weeks of Product Intake — 2.82; 2.21; 2.75 HOMA index

Primary: % Participants Downloading Huma App — 95; 0 Participants

Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16 — -0.46; -0.25; -0.71; -1.08 Percentage of HbA1c in the blood — p=0.2968

Primary: Disposition Index — 0.023; 0.149 index

Primary: Self-Care Activities: Healthy Eating — 4.23; 4.67; 4.61; 4.60 days/week (min: 0 days; Max: 7 days)

Primary: Abnormal Glucose Levels After Colonoscopic Preparation — 2; 0; 185 Participants

Primary: Number of Participants With Established Cardiovascular Disease, or Chronic Kidney Disease, or High Cardiovascular Risk — 127726; 43819; 295882; 99128 Participants

Primary: Number of Enrollees With Diabetes-related Preventable Hospitalizations — 48; 109; 48; 90 Participants

Primary: Mean Change in Hemoglobin A1c (HbA1c) Levels — 0.001; -0.007 mmol/mol

Primary: Glycosylated Hemoglobin Change — 6.82; 7.17; 6.80; 6.33 percentage of glycosylated hemoglobin — p=0.830

Primary: Total Physical Activity Log Means and Geometric Means With Standard Deviation in Intervention and Control Groups After Intervention. — 216.07; 201.47 log calories/day…

Primary: Change in Glucose Levels Between Pre-treatment and End of Treatment as Measured by 24-hour Continuous Glucose Monitoring (CGM) — -4.94; -10.00; -1.21; -11.42 mg/dL…

Primary: Number of Participants Who Experienced at Least One Adverse Event — 1; 1; 0; 1 participants

Primary: Fasting Plasma Glucose <126 mg/dL and HbA1c < 6.5% at Three Years of Follow-up. — 13; 5; 42; 0 % of patients — p=0.60

Primary: Weight Change From Baseline to 12 Months — -.995535; -2.1333341; .039778; -4.17 Pounds

Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 — 0.46; 0.18; -0.07; 0.01 Percentage of HbA1c — p=0.061

Primary: Number of Participants With Combination of All Cause Death, Non-fatal Myocardial Infarction (MI), and Hospitalization for Unstable Angina — 34; 28 Participants